CN103462976B - Incarviatone A在制备抗结核菌药物中的应用 - Google Patents
Incarviatone A在制备抗结核菌药物中的应用 Download PDFInfo
- Publication number
- CN103462976B CN103462976B CN201310441551.7A CN201310441551A CN103462976B CN 103462976 B CN103462976 B CN 103462976B CN 201310441551 A CN201310441551 A CN 201310441551A CN 103462976 B CN103462976 B CN 103462976B
- Authority
- CN
- China
- Prior art keywords
- tubercle bacillus
- incarviatone
- incarviatonea
- tuberculosis
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000193830 Bacillus <bacterium> Species 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 201000008827 tuberculosis Diseases 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 206010034133 Pathogen resistance Diseases 0.000 abstract description 2
- 230000000630 rising effect Effects 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 9
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000002365 anti-tubercular Effects 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310441551.7A CN103462976B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备抗结核菌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310441551.7A CN103462976B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备抗结核菌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103462976A CN103462976A (zh) | 2013-12-25 |
CN103462976B true CN103462976B (zh) | 2015-12-23 |
Family
ID=49788174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310441551.7A Expired - Fee Related CN103462976B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备抗结核菌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103462976B (zh) |
-
2013
- 2013-09-22 CN CN201310441551.7A patent/CN103462976B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103462976A (zh) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105250270A (zh) | Cyanogramide在制备抗结核菌药物中的应用 | |
CN103462976B (zh) | Incarviatone A在制备抗结核菌药物中的应用 | |
CN103381156B (zh) | Chukrasone B在制备抗结核菌药物中的应用 | |
CN103446129B (zh) | Lycojaponicumin A在制备抗结核菌药物中的应用 | |
CN103479631B (zh) | Lycojaponicumin B在制备抗结核菌药物中的应用 | |
CN103446145B (zh) | Lycojaponicumin C在制备抗结核菌药物中的应用 | |
CN102872104B (zh) | Houttuynoid C在抗结核菌药物中的应用 | |
CN103263428A (zh) | Polyflavanostilbene A在制备抗结核菌药物中的应用 | |
CN102872049B (zh) | Gypensapogenin A在制备抗结核菌药物中的应用 | |
CN102872152B (zh) | Houttuynoid D在抗结核菌药物中的应用 | |
CN105456274A (zh) | Flabelliferin B在制备抗结核菌药物中的应用 | |
CN103463012B (zh) | Fluevirosines A在制备治疗抗结核菌药物中的应用 | |
CN105287501A (zh) | Foveospirolide在制备治疗抗结核菌药物中的应用 | |
CN102872091B (zh) | Houttuynoid E在抗结核菌药物中的应用 | |
CN102872055B (zh) | Gypensapogenin B在抗结核菌药物中的应用 | |
CN103638009B (zh) | Artoxanthochromane在治疗抗结核菌药物中的应用 | |
CN105496998A (zh) | Vulgarisin A在制备治疗抗结核菌药物中的应用 | |
CN103356629A (zh) | Myriberine A在制备治疗抗结核菌药物中的应用 | |
CN102872087B (zh) | Houttuynoid A在抗结核菌药物中的应用 | |
CN103006639A (zh) | Aphanamixoid A在制备抗结核菌药物中的应用 | |
CN103285010A (zh) | 化合物在制备治疗抗结核菌药物中的应用 | |
CN105232520A (zh) | Linderolide G在制备治疗抗结核菌药物中的应用 | |
CN103446109A (zh) | Sarcaboside B在抗结核菌药物中的应用 | |
CN103446107A (zh) | Sarcaboside A在抗结核菌药物中的应用 | |
CN105412097A (zh) | Leuconoxine在制备治疗抗结核菌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Hongli Inventor before: Jiang Chunping Inventor before: Huang Rong |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151104 Address after: 325011, building 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Zhejiang, Wenzhou Applicant after: Wenzhou Chengqiao Technology Co.,Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing guangkangxie Biomedical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181212 Address after: 409000 Baijiahe Road, Zhengyang Industrial Park, Qianjiang District, Chongqing Patentee after: CHONGQING QIANJIANG APENG TECHNOLOGY ENTERPRISE INCUBATOR CO.,LTD. Address before: 325011 room 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Wenzhou, Zhejiang. Patentee before: Wenzhou Chengqiao Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151223 Termination date: 20210922 |